Novartis
Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.
DitchCarbon Score
How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis's reported carbon emissions
In 2024, Novartis reported total carbon emissions of approximately 4,587,300,000 kg CO2e, with Scope 1 emissions at about 207,000,000 kg CO2e, Scope 2 emissions at approximately 30,000,000 kg CO2e (market-based), and a significant Scope 3 total of about 4,350,300,000 kg CO2e. This represents a reduction of 63% in Scope 1 and 2 emissions compared to their 2016 baseline, achieved through various initiatives. Novartis has set ambitious climate commitments, aiming to become carbon neutral in its own operations (Scope 1 and 2) by 2025. Additionally, they have pledged to reduce absolute Scope 1 and 2 GHG emissions by 90% and Scope 3 emissions by 42% by 2030, using 2022 as the baseline year. Long-term, the company is committed to achieving net-zero emissions across its value chain by 2040. These targets align with the Science Based Targets initiative (SBTi), which recognises Novartis's commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 35% by 2030 from a 2016 base year. The company is also a signatory of the Climate Pledge, reinforcing its dedication to sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
